Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Developments in clinical trials and health information technology that will improve targeted therapies for patients

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 1869

Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA

Dr Hudis presents, at a press conference at ASCO 2015, three key initiatives designed to advance precision medicine:

The National Cancer Institute-MATCH (NCI-MATCH) trial, co-led by the ECOG-ACRIN Cancer Research Group, which is designed to seek evidence that treating patients based on their tumours' molecular profile, rather than by tumour type, may have clinical benefit

The Targeted Agent and Profiling Utilization Registry (TAPUR), the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications approved by the Food and Drug Administration

CancerLinQ, ASCO's groundbreaking health information technology initiative to achieve higher quality, higher value

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation